Quarterly subscription
What changed this quarter for high-cost drugs in Argentina, and what it means for your products.
Each quarter you receive a 12 to 15 page report and an Excel file with every series. It covers payments from SURGE, the national reimbursement mechanism for high-cost treatments, by social security fund and private insurer; centralized purchasing and tenders, with unit prices compared against list price and reimbursement value; list prices for up to five molecules chosen with you (additional molecules are quoted separately); and the quarter's regulatory and court decisions, each with a one-line implication. It closes with two pages of implications written for your portfolio and a 60-minute session with your team.
The white paper El precio lo fija el que compra (in Spanish) is edition zero of the monitor. Leave us your email and we will send it to you.
We will email it to you the same day. The white papers are in Spanish.
The monitor does not include sales data by payer, interviews with payers (that is what the KHIN Panel is for) or pricing recommendations for a specific product (that is what the Decision Sprint is for).
A Decision Sprint on a molecule in your portfolio that the monitor flags as at risk.